CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01
On December 17, 2019, Capricor Therapeutics, Inc., a Delaware corporation (the “Company”), announced the pricing of an offering of (i) 531,173 shares (the “Shares”) of its common stock, par value $0.001 per share (the “Common Stock”), (ii) warrants to purchase up to 4,139,477 shares of Common Stock (the “Common Warrants”) and (iii) pre-funded warrants (the “Pre-Funded Warrants”) to purchase up to 3,608,304 shares of Common Stock (the “Pre-Funded Warrant Shares”), at a combined purchase price of $1.226 per Share and associated Common Warrant and $1.225 per Pre-Funded Warrant and associated Common Warrant. The Company will issue (a) to each purchaser of Shares in the offering a Common Warrant to purchase a number of shares of Common Stock equal to the number of Shares purchased by such purchaser in the offering, and (b) to each purchaser of Pre-Funded Warrants in the offering a Common Warrant to purchase a number of shares of Common Stock equal to the number of Pre-Funded Warrant Shares underlying the Pre-Funded Warrants purchased by such purchaser in the offering.
Subject to certain ownership limitations described in the Common Warrants, the Common Warrants have an exercise price of $1.10 per share of Common Stock, will be exercisable upon issuance and will expire five years from the date of issuance. If not previously exercised in full, at the expiration of their terms, the Common Warrants will be automatically exercise via cashless exercise. The exercise price of the Common Warrants will be subject to adjustment for stock splits, reverse splits, and similar capital transactions as described in the Common Warrants.
Subject to certain ownership limitations described in the Pre-Funded Warrants, the Pre-Funded Warrants have an exercise price of $0.001 per share, are immediately exercisable and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full.
The Common Warrants and the Pre-Funded Warrants provide that holders will have the right to participate in any rights offering or distribution of assets, and will have the right to receive certain consideration in fundamental transactions, together with the holders of Common Stock on an as-exercised basis. In addition, upon certain fundamental transactions, the holder of the Common Warrants shall have the right to receive payment in cash, or under certain circumstances in other consideration, from the Company at the Black-Scholes value as described in the Common Warrants. A holder will not have the right to exercise any portion of the Common Warrants or Pre-Funded Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% (or, at the election of the holder, 9.99%) of the number of shares of Common Stock outstanding immediately after giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the Common Warrants or the Pre-Funded Warrants, respectively. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon notice to the Company, provided that any increase in such percentage shall not be effective until 61 days after such notice.
In connection with this offering, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single institutional investor. The Purchase Agreement contains customary representations and warranties of the Company, termination rights of the parties, and certain indemnification obligations of the Company and ongoing covenants of the Company, including a prohibition on issuance of Common Stock or securities convertible or exchangeable into Common Stock by the Company for a period of 90 days after the closing date and a prohibition on the Company entering into variable rate transactions for a period of 12 months after closing, subject to certain exceptions. Certain of the Company’s directors also purchased shares of Common Stock and Common Warrants on substantially the same terms as set forth in the Purchase Agreement.
The net proceeds to the Company from the offering are expected to be approximately $4.4 million, after deducting placement agent’s fees and other estimated offering expenses payable by the Company. The Company intends to use the net proceeds from this offering to fund research and development of its exosome technologies to support the filing of an IND in an indication to be designated by us, for related manufacturing costs to support the development of our exosomes technologies, for hiring additional personnel, for business development and for general corporate purposes, which may include additional work around CAP-1002 either alone or in collaboration with a third party. All of the securities in the offering are being sold by the Company.
The offering is being made to the Company’s effective registration statement on Form S-1 (Registration No. 333-235358) previously filed with and declared effective by the Securities and Exchange Commission and a preliminary and final prospectus thereunder. The Company expects that the closing of the offering will take place on or about December 19, 2019, subject to the satisfaction or waiver of customary closing conditions.
On December 17, 2019, the Company issued a press release announcing that the Company had priced the offering of the Common Stock, Pre-Funded Warrants, and Common Warrants. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.
(d) Exhibits
| 1.1 | Form of Securities Purchase Agreement |
| 99.1 | Press release issued December 17, 2019 |
CAPRICOR THERAPEUTICS, INC. Exhibit
EX-1.1 2 tm1926480d1_ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 17,…
To view the full exhibit click here
About CAPRICOR THERAPEUTICS, INC. (NASDAQ:CAPR)
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.